| Name: |
Prof J.(Jan) Meulenbelt, MD, PhD |
| Function: |
Professor of Clinical Toxicology/Director National Poisons Information Center |
| Department: |
Intensive Care Center and National Poisons Information Center |
| Division: |
Division of Anesthesiology, Intensive Care, Clinical Toxicology and Emergency Medicine
Also affiliated with: Institute for Risk Assessment Sciences, Utrecht University, Utrecht |
| E-mail address: |
J.Meulenbelt-1@umcutrecht.nl |
| Phone number: |
+31 (0) 88 75 58561 |
| Fax number: |
+31 (0) 30 25 41511 |
| Visiting address: |
UMC Utrecht
Room B.00.118
Heidelberglaan 100
3584 CX Utrecht
The Netherlands |
| Correspondence: |
UMC Utrecht
P.O. Box 85500
Mail stop B 00.118
3508 GA Utrecht
The Netherlands |
About
Professor Jan Meulenbelt (1951) is internist, intensivist and toxicologist. He moved to the University Medical Center Utrecht in Utrecht and National Institute for Public Health and the Environment in Bilthoven in 1986. His PhD thesis ‘Experimental study to investigate the effects of intervention in acute nitrogen dioxide intoxication to improve human treatment’ is focused on the treatment of ARDS (Adult Respiratory Distress Syndrome) caused by nitrogen dioxide inhalation. He was Chairman of the Scientific Committee of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) from 2000-2002 and President of the EAPCCT from 2002-2004. In 2010 Jan Meulenbelt was awarded honorary fellowship of the American Academy of Clinical Toxicology. He is Deputy editor of Clinical Toxicology and member of several advisory boards concerning public health in the Netherlands.
His current appointment is Director of the National Poisons Information Center at the UMC Utrecht and Professor of Clinical Toxicology at the Institute for Risk Assessment Sciences, Utrecht University, Utrecht. He is also working as intensivist at the Department of Intensive Care Center.
Interest and focus
His research focuses on pharmaco/toxicokinetics and pharmaco/toxicodynamics in order to improve the treatment and safety of patients/persons exposed to xenobiotics (e.g. medicines, drugs of abuse). In this framework he performed and supervised many healthy volunteer and patient studies. He is interested in the acute intoxicated patient needing acute medical care. Especially the interindividual vulnerability for xenobiotics caused by organ failure, drug-drug interaction, age, genetic differences in biotransformation, etc., have his attention. Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and other drug targets are important for interindividual differences in the efficacy, safety and toxicity of many medications.